W hen it comes to treating a chronic condition like migraine, Western medicine is the new kid on the block, relatively speaking. After all, the vast majority of today’s pharmace ...

Pfizer’s Vydura has become the first oral CGRP antagonist recommended for routine use by the NHS to prevent episodic migraine attacks, after being rejected earlier this year as an acute treatment.

The following is a summary of “A National Cross-Sectional Survey on Real-World Experiences of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody Use in Adults with Migraine in Finland,” ...

The CHRONICLE study, 5 published in The Lancet Neurology, provides open-label safety data on 131 participants with chronic cluster headache who received four cycles of 400 mg eptinezumab, another CGRP ...